Related to Positive Results Reported for Biogen Idec’s Oral MS Drug in First Phase III Study

• Genentech and Biogen Idec Report Positive Late-Stage Data with RA Therapy
  
• Acorda Obtains FDA Nod for Oral Drug that Improves Walking in MS Patients
  
• Biogen Idec Takes Over Development of Hemophilia Therapies in Deal with Swedish Orphan Biovitrum
  
• FDA Grants New Approval for Rituxan in CD20-Positive CLL
  
• Roche and Biogen Idec Put the Brakes on Development of Ocrelizumab in RA
  
• Fast Forward and JDRF Team Up with Axxam for MS and Diabetes Treatments
  
• AVEO Earns $5M Milestone from Biogen Idec as Part of ErbB3 Antibody Collaboration
  
• Cannabis-Based Drug Launched in the U.K. for MS Spasticity
  
• Spain Approves Cannabis-Derived MS Therapy as GW Pharm Files for New EU Approvals
  
• Monash University Collaborates with Cryo-Cell to Investigate Menstrual Stem Cell Therapy for MS
  
• Biogen Licenses Knopp’s Phase III-Ready ALS Drug for $80M
  
• Canada Grants GW Pharm’s Sativex Full Approval for MS Spasticity
  
• Russian Authorities Become First to Sanction Novartis’ Oral MS Therapy
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease
  
• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• Accentia Secures Rights to Baxter’s Cyclophosphamide for Autoimmune Candidate
  
• Biogen Idec Picks Up Neurimmune's Neurodegenerative Programs for $32.5M
  
• CHMP Upholds Previous Negative Opinion on Merck KGaA’s MS Therapy
  
• Novartis Wins Positive Recommendation for Its MS Drug from CHMP